多国早期抗病毒治疗研究中诊断急性与早期HIV感染的新标准
AIDS临床试验组A5354研究在2017-2019年纳入195名符合6项标准之一的成人,评估基于HIV RNA、抗体、Western blot或Geenius及ARCHITECT S/CO比值的急性/早期HIV感染诊断标准。集中检测确认188例(96.4%)为AEHI;回顾性分析显示Geenius抗体无反应或不确定联合ARCHITECT S/CO≥10可正确识别99/122(81.2%)Fiebig II-IV期AEHI且无假阳性。
要点
- Geenius抗体无反应/不确定联合ARCHITECT S/CO≥10可识别81.2%的Fiebig II-IV期AEHI。
- 新标准无需等待HIV RNA结果即可快速启动ART。
- 集中检测确认96.4%入组者为AEHI。
核心结论
- 纳入ARCHITECT S/CO比值的新AEHI标准可促进快速高效启动ART而无需等待HIV RNA结果。
研究设计与样本
- AIDS临床试验组A5354前瞻性研究,在美洲、非洲和亚洲30个中心纳入195名符合6项标准之一的成人。
主要发现
- 195名参与者中位年龄27岁(IQR 23-39),30名(15.4%)为女性。
- 171名(87.7%)在入组当天启动ART,24名(12.3%)次日启动。
- 集中检测确认188名(96.4%)为AEHI,4名(2.0%)为慢性感染,3名(1.5%)无HIV并终止ART退出。
- 回顾性分析中,Geenius抗体无反应或不确定联合ARCHITECT S/CO≥10正确识别99/122(81.2%)Fiebig II-IV期AEHI病例,无假阳性。
关键数值与推荐
- Geenius抗体无反应或不确定联合ARCHITECT S/CO≥10:识别81.2%(99/122)Fiebig II-IV期AEHI,无假阳性。
临床怎么用
- 在临床实践和未来研究中,可采用结合ARCHITECT S/CO比值的AEHI标准快速诊断、分期并立即启动ART。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antiretroviral therapy (ART) initiation during acute and early human immunodeficiency virus infection (AEHI) limits HIV reservoir formation and may facilitate post-ART control but is logistically challenging. We evaluated the performance of AEHI diagnostic criteria from a prospective study of early ART initiation. METHODS: AIDS Clinical Trials Group A 5354 enrolled adults at 30 sites in the Americas, Africa, and Asia who met any 1 of 6 criteria based on combinations of results of HIV RNA, HIV antibody, Western blot or Geenius assay, and/or the signal-to-cutoff (S/CO) ratio of the ARCHITECT HIV Ag/Ab Combo or GS HIV Combo Ag/Ab EIA. HIV status and Fiebig stage were confirmed by centralized testing. RESULTS: From 2017 through 2019, 195 participants were enrolled with median age of 27 years (interquartile range, 23-39). Thirty (15.4%) were female. ART was started by 171 (87.7%) on the day of enrollment and 24 (12.3%) the next day. AEHI was confirmed in 188 (96.4%) participants after centralized testing, 4 (2.0%) participants were found to have chronic infection, and 3 (1.5%) found not to have HIV discontinued ART and were withdrawn. Retrospectively, a nonreactive or indeterminate HIV antibody on the Geenius assay combined with ARCHITECT S/CO ≥10 correctly identified 99 of 122 (81.2%) Fiebig II-IV AEHI cases with no false-positive results. CONCLUSIONS: Novel AEHI criteria that incorporate ARCHITECT S/CO facilitated rapid and efficient ART initiation without waiting for an HIV RNA result. These criteria may facilitate AEHI diagnosis, staging, and immediate ART initiation in future research studies and clinical practice. CLINICAL TRIALS REGISTRATION: NCT02859558.
引用
- Crowell TA, Ritz J, Coombs RW, et al. Novel Criteria for Diagnosing Acute and Early Human Immunodeficiency Virus Infection in a Multinational Study of Early Antiretroviral Therapy Initiation. Clin Infect Dis. 2021. PMID: 33382405. doi:10.1093/cid/ciaa1893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。